🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Afatinib 40 mg

$118.00$4.21 per tablet · 28 tablets

Afatin 30 mg & 40 mg Tablets are used for non-small cell lung cancer. Get them at the best rate with quick shipping in the US, UK & Australia!

Choose pack sizePrice per tablet shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in discreet packaging with a tracking number. Delivery time for this product: 6 to 15 days. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email order@pharmeasybank.com.

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

What Is Afatinib 40 mg?

Afatinib 40 mg is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class.

It is primarily used in selected patients with advanced or metastatic non-small cell lung cancer (NSCLC), particularly when the tumor contains susceptible mutations in the epidermal growth factor receptor (EGFR) gene.

EGFR is a cell-surface receptor involved in regulating cell growth, division and survival.

Certain mutations in the EGFR gene can cause abnormal receptor activity, allowing cancer cells to grow and multiply uncontrollably.

Afatinib works by irreversibly inhibiting several receptors belonging to the ErbB family, including EGFR (ErbB1), HER2 (ErbB2) and ErbB4.

By blocking these receptors, afatinib interferes with cellular signaling pathways that promote cancer growth and survival.

Afatinib is commonly classified as a second-generation EGFR tyrosine kinase inhibitor.

Unlike conventional cytotoxic chemotherapy, afatinib targets specific molecular pathways associated with cancer cell growth.

However, EGFR signaling is also important in normal tissues, particularly the skin and gastrointestinal tract.

Consequently, diarrhea, skin rash, mouth inflammation and nail changes are common treatment-related adverse effects.

How Does Afatinib 40 mg Work?

1. Targets ErbB Family Receptors

Afatinib inhibits receptor tyrosine kinases belonging to the ErbB family.

These receptors regulate important cellular growth and survival pathways.

2. Inhibits EGFR Signaling

Certain EGFR mutations produce abnormal signaling that promotes cancer cell growth.

Afatinib blocks the kinase activity of susceptible EGFR receptors.

3. Forms an Irreversible Bond

Afatinib forms a covalent bond with the kinase domains of targeted receptors.

This produces irreversible inhibition of receptor activity.

4. Suppresses Growth-Promoting Pathways

Afatinib interferes with intracellular signaling pathways involved in cell proliferation and survival.

5. Reduces Cancer Cell Proliferation

By inhibiting abnormal receptor signaling, afatinib may slow the multiplication of susceptible cancer cells.

6. Promotes Cancer Cell Death

In certain EGFR-dependent tumors, inhibition of signaling can promote apoptosis.

7. Helps Control Tumor Growth

Afatinib may reduce tumor size or delay disease progression in appropriately selected patients.

8. Provides Molecularly Targeted Treatment

Its effectiveness depends significantly on the tumor’s molecular characteristics and susceptibility to EGFR inhibition.

Important: Not all EGFR mutations respond equally to afatinib. Resistance mutations and other molecular changes can reduce treatment effectiveness.

Uses of Afatinib 40 mg

1. EGFR Mutation-Positive Non-Small Cell Lung Cancer

Afatinib is used to treat selected patients with advanced or metastatic NSCLC containing susceptible EGFR mutations.

Treatment selection depends on molecular testing and current oncology guidelines.

2. EGFR Exon 19 Deletion-Positive NSCLC

Afatinib has established activity against certain EGFR exon 19 deletion mutations.

However, newer targeted therapies may be preferred in many current treatment settings.

3. EGFR L858R Mutation-Positive NSCLC

Afatinib may be used in selected patients whose tumors contain the EGFR exon 21 L858R mutation.

4. Selected Uncommon EGFR Mutations

Afatinib has demonstrated activity against certain uncommon EGFR mutations, including:

  • G719X
  • L861Q
  • S768I

The clinical relevance depends on the specific mutation, treatment history and applicable regulatory approval.

5. Advanced Non-Small Cell Lung Cancer

Afatinib may be prescribed for locally advanced or metastatic disease when tumor characteristics support its use.

6. Metastatic NSCLC

In eligible patients, afatinib may help control tumor growth and delay disease progression.

7. Previously Treated Squamous NSCLC

Afatinib has an approved indication in certain jurisdictions for metastatic squamous NSCLC that progresses after platinum-based chemotherapy.

Its current role depends on available treatment alternatives and clinical guidelines.

8. EGFR-Targeted Cancer Therapy

Afatinib may be selected when an oncologist determines that irreversible ErbB inhibition is appropriate for the patient’s cancer.

9. Individualized Oncology Treatment

Treatment decisions may consider EGFR mutation status, prior therapies, other medical conditions and expected tolerability.

10. Long-Term Disease Control

When effective and tolerated, afatinib may be continued to help control cancer progression.

Important: Afatinib should not be promoted as a universal treatment for lung cancer or as effective against every EGFR mutation.

How to Take Afatinib 40 mg

Afatinib must be taken strictly according to the oncology specialist’s prescription.

General Administration Instructions

  1. Confirm the prescribed strength and treatment schedule.
  2. Take afatinib at approximately the same time each day.
  3. Take the tablet on an empty stomach.
  4. Avoid food for at least 3 hours before and 1 hour after taking afatinib.
  5. Swallow the tablet whole with water.
  6. Do not independently increase or reduce the dose.
  7. Do not take additional tablets to compensate for a missed dose.
  8. Report persistent diarrhea, severe skin reactions or breathing difficulties promptly.
  9. Attend scheduled oncology appointments and laboratory tests.
  10. Follow any prescribed dose interruption or reduction plan.

Is Afatinib 40 mg Taken Daily?

Afatinib is generally administered once daily.

The exact schedule must follow the oncology prescription.

Should Afatinib Be Taken With Food?

No. Afatinib should generally be taken on an empty stomach because food can reduce drug exposure.

Can Afatinib 40 mg Be Taken at Night?

Afatinib may be taken at a consistent time that accommodates the required fasting interval, according to the prescriber’s instructions.

Can Afatinib Tablets Be Crushed?

Afatinib tablets should generally be swallowed whole.

For patients who cannot swallow tablets, certain product instructions describe dispersion in noncarbonated water.

Use an alternative administration method only with guidance from the oncology team and the specific product labeling.

What If a Dose Is Missed?

Under standard afatinib labeling, a missed dose may be taken when remembered unless the next scheduled dose is within 12 hours.

If the next dose is within 12 hours, skip the missed dose.

Do not double the dose.

What If Too Much Afatinib Is Taken?

An overdose may cause serious gastrointestinal, skin and other toxicities.

Seek urgent medical attention.

How Long Does Afatinib 40 mg Take to Work?

The response to afatinib depends on the tumor’s EGFR mutation, disease characteristics and individual treatment response.

After Administration

Afatinib is absorbed and begins inhibiting susceptible ErbB receptor signaling.

During the First Several Weeks

Biological effects on susceptible cancer cells may occur.

During Early Treatment Assessment

Imaging studies may demonstrate tumor shrinkage or disease stabilization.

During Continued Treatment

The oncology team evaluates treatment effectiveness, adverse reactions and possible disease progression.

Important: Treatment response must be assessed through clinical evaluation and imaging rather than symptoms alone.

Common Side Effects

Possible side effects include:

  • Diarrhea
  • Acne-like skin rash
  • Dry skin
  • Itching
  • Mouth sores
  • Fatigue
  • Nosebleeds
  • Eye irritation
  • Elevated liver enzymes

Diarrhea and skin reactions are particularly important because they may become severe and require medical treatment, dose interruption or dose reduction.

Serious Side Effects

Seek urgent medical attention if any of the following occur:

  • Severe or persistent diarrhea
  • Signs of dehydration
  • Significant reduction in urine output
  • New or worsening shortness of breath
  • Persistent cough with fever
  • Severe blistering or peeling skin
  • Severe mouth inflammation
  • Yellowing of the skin or eyes
  • Severe abdominal pain
  • Sudden vision changes
  • Severe eye pain
  • Significant weakness or dizziness

Important Serious Risks

Severe Diarrhea: Afatinib can cause severe diarrhea, dehydration and electrolyte disturbances.

Dehydration and Kidney Injury: Persistent diarrhea may lead to dehydration and acute kidney injury.

Interstitial Lung Disease: Rare but potentially fatal interstitial lung disease or pneumonitis may occur.

Severe Skin Reactions: Serious dermatological reactions, including blistering and exfoliative skin conditions, have been reported.

Hepatotoxicity: Afatinib may cause serious liver injury, including rare fatal cases.

Keratitis: Corneal inflammation and other eye complications may occur.

Cardiac Dysfunction: Afatinib may affect left ventricular function in some patients.

Embryo-Fetal Toxicity: Afatinib can harm a developing fetus.

Contraindications & Precautions

1. Allergy to Afatinib

Patients with known serious hypersensitivity to afatinib or formulation ingredients should not use the medicine.

2. EGFR Mutation Testing

Molecular testing is important when selecting afatinib for EGFR mutation-directed NSCLC treatment.

3. Severe Diarrhea

Persistent or severe diarrhea requires prompt medical management.

4. Dehydration

Patients experiencing diarrhea or vomiting are at risk of dehydration and electrolyte abnormalities.

5. Kidney Disease

Patients with kidney impairment require careful evaluation. Dose adjustment may be necessary in severe renal impairment.

6. Liver Disease

Patients with liver impairment require monitoring for potential hepatotoxicity.

7. Interstitial Lung Disease

New or worsening respiratory symptoms require immediate medical assessment.

8. Severe Skin Reactions

Severe rash, blistering or peeling skin requires prompt evaluation.

9. Eye Disorders

Patients with eye pain, redness, light sensitivity or vision changes should seek medical attention.

10. Heart Disease

Patients with cardiac risk factors may require additional assessment and monitoring.

11. Pregnancy

Afatinib can cause fetal harm and should generally be avoided during pregnancy.

12. Breastfeeding

Breastfeeding is not recommended during treatment and for the period specified in the product labeling after the final dose.

13. Fertility

Reproductive planning and fertility considerations should be discussed before treatment.

14. Drug Interactions

Potential interactions include medicines affecting P-glycoprotein (P-gp), such as:

  • Rifampicin
  • Ritonavir
  • Cyclosporine
  • Certain P-gp inhibitors
  • Certain P-gp inducers

Interaction management may require changes in administration timing, dose or treatment selection.

15. Food Interactions

Food reduces afatinib exposure.

The recommended fasting interval should be followed.

16. Medication Adherence

Consistent dosing is important for maintaining appropriate treatment exposure.

17. Dose Reduction

Significant adverse reactions may require treatment interruption or dose reduction.

18. Medical Monitoring

Healthcare professionals may assess:

  • EGFR mutation status
  • Cancer stage
  • Treatment response
  • Imaging findings
  • Weight changes
  • Nutritional status
  • Medication interactions
  • Need for dose interruption
  • Need for dose reduction
  • Disease progression

Potential Therapeutic Advantages

  • Targeted Anticancer Activity.
  • EGFR Tyrosine Kinase Inhibition.
  • Irreversible ErbB Receptor Inhibition.
  • Oral Tablet Formulation.
  • Molecularly Guided Treatment Selection.
  • Cancer Growth Signaling Inhibition.
  • Potential Tumor Growth Control.
  • Dose Adjustment Options.
  • Specialist-Directed Long-Term Treatment.

Disadvantages / Limitations

  • Not Suitable for Every Lung Cancer.
  • Rare Interstitial Lung Disease Risk.
  • Potential Eye Complications.
  • Potential Cardiac Effects.
  • Pregnancy-Related Harm.
  • Requires Empty-Stomach Administration.
  • Potential Drug Interactions.
  • May Require Dose Reduction.
  • Requires Regular Oncology Monitoring.
  • Cancer May Develop Treatment Resistance.
  • Does Not Guarantee a Cure.

Important Notes

Generic Name: Afatinib.

Strength: 40 mg.

Drug Class: Tyrosine Kinase Inhibitor.

Therapeutic Category: Targeted Anticancer Medicine.

Mechanism of Action: Irreversible ErbB Receptor Tyrosine Kinase Inhibition.

Primary Indication: Selected EGFR Mutation-Positive NSCLC.

Route: Oral.

Typical Adult Starting Dose: 40 mg Once Daily for Certain Approved Indications.

Breastfeeding: Not Recommended During Treatment.

Medical Supervision: Oncology Specialist Required.

Storage: Follow Manufacturer Instructions.

Frequently Asked Questions

1. What is Afatinib 40 mg used for?

Afatinib is used to treat selected forms of advanced or metastatic non-small cell lung cancer, particularly tumors containing susceptible EGFR mutations.

2. Is Afatinib 40 mg a chemotherapy medicine?

Afatinib is a targeted anticancer medicine classified as a tyrosine kinase inhibitor. It differs from conventional cytotoxic chemotherapy.

3. How does Afatinib work?

It irreversibly inhibits certain ErbB receptor tyrosine kinases, including EGFR, and interferes with cancer growth signaling.

4. Is Afatinib 40 mg used for lung cancer?

Yes. Afatinib is used in selected NSCLC patients when the tumor’s molecular characteristics and treatment history support its use.

5. Does Afatinib require EGFR testing?

EGFR mutation testing is important when selecting afatinib for mutation-directed NSCLC treatment.

6. Is Afatinib 40 mg a standard starting dose?

For certain approved adult NSCLC indications, 40 mg once daily is the usual starting dose.

7. Can Afatinib 40 mg be taken daily?

Yes. Afatinib is generally administered once daily according to the oncology prescription.

Product DetailsInformation
Product NameAfatinib 40 mg
Generic NameAfatinib
Active IngredientAfatinib (commonly supplied as Afatinib Dimaleate)
Strength40 mg
Dosage FormOral Film-Coated Tablet
Drug ClassTyrosine Kinase Inhibitor (TKI)
Therapeutic CategoryOncology / Targeted Anticancer Medicine
Primary UsesSelected EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Mechanism of ActionIrreversible Inhibition of ErbB Family Receptor Tyrosine Kinases
Route of AdministrationOral
Typical Adult Starting Dose40 mg Once Daily for Certain Approved Indications
Treatment DurationUntil Disease Progression or Unacceptable Toxicity
ManufacturerDepends on Brand
Brand NameNot Specified
Pack SizeDepends on Manufacturer
Prescription StatusPrescription-Only Anticancer Medicine
StorageFollow Manufacturer Instructions
Medical SupervisionOncology Specialist Required
Pack sizes28 tablets, 56 tablets, 84 tablets
Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.